caa a22 4500 465789471 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216928 doi (NATIONALLICENCE)springer-10.1007/BF00216928 Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study [Elektronische Daten] [Sarah Taylor, Thomas Fleming, Daniel Von Hoff, Joseph McCracken, Ronald Bukowski, Robert Talley, Robert Natale, J. Guy, Wolfram Samlowski, John Costanzi] Summary: Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin ⩽ 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients. Kluwer Academic Publishers, 1990 mitoxantrone nationallicence pancreatic carcinoma nationallicence phase II trial nationallicence DHAD nationallicence novantrone nationallicence Taylor Sarah University of Kansas Medical Center, USA aut Fleming Thomas Southwest Oncology Group Biostatistical Center, Seattle aut Von Hoff Daniel University Texas Health Science Center, San Antonio aut McCracken Joseph Brooke Army Medical Center, USA aut Bukowski Ronald Cleveland Clinic Foundation, USA aut Talley Robert Henry Ford Hospital, USA aut Natale Robert University of Michigan Medical Center, USA aut Guy J. Ohio State University Hospital, USA aut Samlowski Wolfram University of Utah Medical Center, USA aut Costanzi John University of Texas, Galveston, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 77-80 0167-6997 8:1<77 1990 8 10637 https://doi.org/10.1007/BF00216928 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216928 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Taylor Sarah University of Kansas Medical Center, USA aut NATIONALLICENCE 700 1- Fleming Thomas Southwest Oncology Group Biostatistical Center, Seattle aut NATIONALLICENCE 700 1- Von Hoff Daniel University Texas Health Science Center, San Antonio aut NATIONALLICENCE 700 1- McCracken Joseph Brooke Army Medical Center, USA aut NATIONALLICENCE 700 1- Bukowski Ronald Cleveland Clinic Foundation, USA aut NATIONALLICENCE 700 1- Talley Robert Henry Ford Hospital, USA aut NATIONALLICENCE 700 1- Natale Robert University of Michigan Medical Center, USA aut NATIONALLICENCE 700 1- Guy J. Ohio State University Hospital, USA aut NATIONALLICENCE 700 1- Samlowski Wolfram University of Utah Medical Center, USA aut NATIONALLICENCE 700 1- Costanzi John University of Texas, Galveston, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 77-80 0167-6997 8:1<77 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer